Quote | Oaktree Acquisition Corp. II Class A (NYSE:OACB)
Last: | $9.38 |
---|---|
Change Percent: | -1.16% |
Open: | $9.58 |
Close: | $9.38 |
High: | $9.59 |
Low: | $9.36 |
Volume: | 23,084 |
Last Trade Date Time: | 06/15/2022 04:40:11 am |
News | Oaktree Acquisition Corp. II Class A (NYSE:OACB)
Alvotech and SPAC Oaktree Acquisition Corp. II (NYSE:OACB) on Tuesday said that their planned merger was approved by OACB shareholders. OACB agreed to take Alvotech, a biopharmaceutical company developing biosimilars, public in Dec. 2021 at a $2.25B valuation. The merger is anticipated to clo...
Business Combination anticipated to close on or about June 15, 2022 Ordinary shares of Alvotech expected to trade under the new ticker symbol “ALVO” from June 16, 2022 on The Nasdaq Stock Market in New York and from June 23, 2022 on the Nasdaq First Nor...
Message Board Posts | Oaktree Acquisition Corp. II Class A (NYSE:OACB)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Oaktree Acquisition Corp. II Class A Company Name:
OACB Stock Symbol:
NYSE Market:
Business Combination anticipated to close on or about June 15, 2022 Ordinary shares of Alvotech expected to trade under the new ticker symbol “ALVO” from June 16, 2022 on The Nasdaq Stock Market in New York and from June 23, 2022 on the Nasdaq First Nor...
Business Combination remains subject to satisfaction of customary closing conditions, including shareholder approval Oaktree Acquisition Corp. II (NYSE: OACB) (“OACB” or the “Company”) announced today that, assuming satisfaction of the conditions ...
The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara ® (ustekinumab) met its primary endpoint AVT04 (ustekinumab) is part of a broader pipeline of Alvotech’s biosimilars and biosimilar candidates, which includes AVT02 (ada...